The Amendments to the Specification

Please replace the paragraph at page 1, lines 15-16 with the following:

The present invention relates to orally-administered pharmaceutical compositions containing interferon-tau and methods of ~~uses~~ use thereof.

Please replace the reference line at page 1, line 30 with the following:

Bazer, F.W., et al., PCT Application ~~publication~~ Publication No. WO 94/10313, published 11 May, 1994.

Please replace the paragraph at page 17, lines 7-17 with the following:

In addition to preventing the onset of symptoms associated with EAE, orally-administered OvIFNτ prevents paralysis in a chronic-relapsing model of EAE, as detailed in Example 3. Whereas 5/5 mice immunized with MBP (to induce EAE) which did not receive OvIFNτ treatment developed chronic relapsing paralysis, 4/5 animals treated with OvIFNτ (either i.p. injection or oral feeding, administered every 48 hours) were fully protected from the disease (Figs. 2B and 2C). These data further support the results described above, and indicate that oral administration of IFNτ can block the development of chronic relapsing EAE. The experiments also suggest that ~~orally-administration~~ oral-administration of IFNτ as infrequently as once every 48 hours, over an extended period of time, is as effective as i.p. injection at treating a disease condition responsive to treatment by interferon-tau.

Please replace the ingredient listed at page 26, line 14 with the following:

11.5 g ~~$Na_2HPO4\text{-}7H_2O$~~ $Na_2HPO_4\text{-}7H_2O$

Please replace the title of Table 4 at page 34, lines 2-3 with the following:

Sera from Mice Treated with OvIFNτ by ~~i.p.~~ I.P. Injection or Oral Feeding ~~do~~ Do Not Possess Neutralizing Activity